IP Library Granted Patent US 10,864,154
Granted Patent B2
US 10,864,154 · App. 16/372,663 · Granted Dec 15, 2020

Skin care compositions and their applications

Inventors: Muhammed Majeed (Bangalore, IN); Kalyanam Nagabhushanam (East Windsor, NJ); Lakshmi Mundkur (Bangalore, IN)
Assignee: SAMI LABS LIMITED
A61K8/676A61K8/39A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,864,154
App. No.
16/372,663
Granted
Dec 15, 2020
Kind
B2
Abstract

The present invention discloses a synergistic composition comprising 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids for use as a skin lightening agent. The invention also discloses a method of inhibiting melanin biosynthesis and tyrosinase activity in mammalian skin cells using a composition comprising 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids.

Claims (12)

1. A method of inhibiting melanogenesis in mammalian skin cells, comprising a step of bringing into contact skin cells with a composition essentially consisting of 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids, to bring about a reduction in melanin synthesis, wherein the 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids are present in the concentrations of 0.5-500 μg/ml and 3-100 μg/ml respectively.

2. The method as in claim 1 , wherein the tetrahydrocurcuminoids comprises of tetrahydrocurcumin, tetrahydrodemethoxycurcumin, tetrahydrobisdemethoxycurcumin.

3. The method as in claim 1 , wherein the tetrahydrocurcuminoids comprises of tetrahydrocurcumin and tetrahydrodemethoxycurcumin.

4. The method as in claim 1 , wherein the tetrahydrocurcuminoids is greater than 95% w/w tetrahydrocurcumin.

5. The method as in claim 1 , wherein the mammalian skin cells are melanocytes.

6. The method as in claim 1 , wherein the mammal is human.

7. A method of inhibiting tyrosinase activity in mammalian skin cells, comprising a step of bringing into contact skin cells with a composition essentially consisting of 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids, to bring about a reduction in melanin synthesis, wherein the 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids are present in the concentrations of 0.5-500 μg/ml and 3-100 μg/ml respectively.

8. The method as in claim 7 , wherein the tetrahydrocurcuminoids comprises of tetrahydrocurcumin, tetrahydrodemethoxycurcumin, tetrahydrobisdemethoxycurcumin.

9. The method as in claim 7 , wherein the tetrahydrocurcuminoids comprises of tetrahydrocurcumin and tetrahydrodemethoxycurcumin.

10. The method as in claim 7 , wherein the tetrahydrocurcuminoids is greater than 95% w/w tetrahydrocurcumin.

11. The method as in claim 7 , wherein the mammalian skin cells are melanocytes.

12. The method as in claim 7 , wherein the mammal is human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2020
From: MAJEED, MUHAMMED, DR; NAGABHUSHANAM, KALYANAM, DR; MUNDKUR, LAKSHMI, DR
To: SAMI LABS LIMITED
Reel/Frame 053894/0249 →
Continuity (1)
Related Publication 20190298641A1 · Oct 3, 2019
Cited By (1)
US 12,521,335